Chia Hung Chin
Chairman at YI CHUN GREEN TECHNOLOGY CO., LTD.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Yue Ching Li | M | - | - | |
Hsi Chun Chin | M | - | 5 years | |
Ming Cheng Lin | M | - | 6 years | |
Sheng Yuan Qu | M | - | 3 years | |
Wen Hsiang Lai | M | - | 18 years | |
Ming Te Su | M | - | 14 years | |
En Guang Mao | M | - | 3 years | |
Hsuan Pin Lai | M | - | 2 years | |
Pei Jen Wu | M | - | 5 years | |
Chun Fu Chang | M | - | 4 years | |
Mao Lin Shih | M | - | 4 years | |
Chin Chi Chen | M | - | 3 years | |
Sheng Chung Lin | M | 72 | 3 years | |
Chung Chiu Huang | M | - | 4 years | |
Kuang Ming Li | M | - | 17 years | |
Chih Chang Chen | M | - | 12 years | |
Ko Ming Lin | M | - | 5 years | |
Tien Cheng Yang | M | - | - | |
Pi Hua Lin | F | - | - | |
Huei Hua Lai | F | - | 3 years | |
Kuo Chin Chen | M | - | 2 years | |
Yu Ling Zhang | M | - | - | |
Ming Zheng Lin | M | - | - | |
Ying Feng Hung | F | - | 3 years | |
Yue Fen Chi | F | - | 2 years | |
Sui Chun Chou | F | - | 2 years | |
Xing Xue Chen | F | - | 9 years | |
Hui Sen Hu | M | - | 2 years | |
Shih Ta Chen | M | - |
Yi-Chiu International Development Co. Ltd.
Yi-Chiu International Development Co. Ltd. Financial ConglomeratesFinance Yi-Chiu International Development Co. Ltd. is a Taiwanese company that provides investment and management consulting services. The private company is based in New Taipei, Taiwan. The company was founded in 2012. | - |
Wen Ching Hsu | M | - |
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Ko Chih Liao | M | - |
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Ming Kung Yeh | M | - |
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Chang En Tsai | M | - |
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Chia Mei Chang | F | - |
Yi-Chiu International Development Co. Ltd.
Yi-Chiu International Development Co. Ltd. Financial ConglomeratesFinance Yi-Chiu International Development Co. Ltd. is a Taiwanese company that provides investment and management consulting services. The private company is based in New Taipei, Taiwan. The company was founded in 2012. | - |
Huan Chieh Chen | F | - |
Yi-Chiu International Development Co. Ltd.
Yi-Chiu International Development Co. Ltd. Financial ConglomeratesFinance Yi-Chiu International Development Co. Ltd. is a Taiwanese company that provides investment and management consulting services. The private company is based in New Taipei, Taiwan. The company was founded in 2012. | - |
Chun Yu Pan | M | - |
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Sheng Hao Chou | M | - | 18 years | |
Chun Cheng Lai | M | - | 4 years | |
Min Feng Chen | M | - | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Taiwan | 39 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chia Hung Chin
- Personal Network